Source author record

Marouen Ben Guebila

Marouen Ben Guebila appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
2topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2021arXiv

Gene targeting in disease networks

Profiling of whole transcriptomes has become a cornerstone of molecular biology and an invaluable tool for the characterization of clinical phenotypes and the identification of disease subtypes. Analyses of these data are becoming ever more sophisticated as we move beyond simple comparisons to consider networks of higher-order interactions and associations. Gene regulatory networks model the regulatory relationships of transcription factors and genes and have allowed the identification of differentially regulated processes in disease systems. In this perspective we discuss gene targeting scores, which measure changes in inferred regulatory network interactions, and their use in identifying disease-relevant processes. In addition, we present an example analysis or pancreatic ductal adenocarcinoma demonstrating the power of gene targeting scores to identify differential processes between complex phenotypes; processes which would have been missed by only performing differential expression analysis. This example demonstrates that gene targeting scores are an invaluable addition to gene expression analysis in the characterization of diseases and other complex phenotypes.

preprint2016arXiv

Toward a closed-loop subcutaneous delivery of L-DOPA

L-DOPA has been the gold standard treatment for Parkinson's disease since 50 years. Being the direct biochemical precursor of dopamine, L-DOPA is effectively converted in the brain, but two major phenomena reduce its therapeutic action: i) competition with amino acids in the gut wall and in the blood brain barrier and ii) its fast kinetics (absorption, distribution, metabolism, and elimination). Continuous administration of L-DOPA, such as jejunal pumps, have addressed the issue of fast absorption. Considering a subcutaneous delivery of L-DOPA allows to bypass the gastrointestinal tract and avoid competition with dietary amino acids. Remains the competition at the blood barrier between amino acids and L-DOPA, which we address by proposing a closed-loop controlled, continuous subcutaneous delivery pump. In the proof-of-concept format, the delivery strategy evaluated on comprehensive model of L-DOPA kinetics, holds the promise of improving the treatment of late-stage Parkinson's disease patients.